February 1, 2024 in Home Page, Nanoscope Press Release

Nanoscope Therapeutics Announces Presentation at Bascom Palmer Eye Institute’s 21st Annual Angiogenesis, Exudation, and Degeneration Meeting

Comments Off on Nanoscope Therapeutics Announces Presentation at Bascom Palmer Eye Institute’s 21st Annual Angiogenesis, Exudation, and Degeneration Meeting

DALLAS, February 1, 2024 — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), tod ...

Read More
January 18, 2024 in Home Page, Nanoscope Press Release

Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa

Comments Off on Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa

FDA and EU Regulators provide consistent advice that visual acuity may serve as primary endpoint to evaluate the effectiveness of MCO-010 in the treatment of low-vision retinitis pigmentosa (RP) patie ...

Read More
December 4, 2023 in Home Page, Nanoscope Press Release

Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the Board

Comments Off on Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the Board

New Addition Highlights Continued Enhancement of Organization’s Strategic Trajector Dallas, TX – December 4, 2023 – Nanoscope Therapeutics (Nanoscope), a clinical-stage biotechnology company de ...

Read More
November 9, 2023 in Home Page, Nanoscope Press Release

Nanoscope Therapeutics to Present at the 4th Annual Dry AMD Therapeutic Development Summit

Comments Off on Nanoscope Therapeutics to Present at the 4th Annual Dry AMD Therapeutic Development Summit

DALLAS, Nov. 9, 2023  -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today ...

Read More
September 13, 2022 in Home Page, Nanoscope Press Release

Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease

Comments Off on Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease

Six-month data from Phase 2 STARLIGHT trial expected in H1 2023DALLAS, Sept. 13, 2022  -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal dege ...

Read More
February 7, 2022 in Home Page, Nanoscope Press Release

Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision

Comments Off on Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision

DALLAS, Feb. 7, 2022  -- Nanoscope Therapeutics, a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced full enrollment of its Phase 2b cli ...

Read More